Tampa General Hospital Cancer Institute
Tampa, FL
Accepting patients
BGB-11417
A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies
- BCL-2 Inhibitor
- Phase 1/2
- Has results
Accepting patients